Introduction
============

Animals and plants express hundreds of miRNAs, which are predicted to target and regulate at least 60% of protein-coding mRNAs and are integral to almost all known biological processes. DICER1 is highly conserved throughout evolution, and contains several functionally important domains. We and others have identified both germ-line and somatic mutations in *DICER1* that are associated with a range of mainly childhood-onset cancers and dysontogenic or hyperplastic conditions, notably "blastoma"-type tumors such as pleuropulmonary blastoma (PPB), ovarian Sertoli- Leydig cell tumor (SLCT), embryonal rhabdomyosarcoma and Wilms tumor, as well as benign tumors such as cystic nephroma \[[@B1]-[@B10]\]. Despite a detailed study of hundreds of cancer cell lines \[[@B4]\], the full extent and limit of the involvement of both germ-line and somatic *DICER1* mutations in rarer types of human cancer is currently unknown.

A large study of all exons of *DICER1*, conducted using DNA from 4 microsatellite-stable testicular germ cell tumor (TGCT) cell lines and germ-line DNA from 185 persons with a germ cell tumor (of whom 71 had a seminoma and 128 of whom had a family history of TGCT) revealed one germ-line mutation, c.4740G \> T, p.Q1580H, in a man with a past personal history of seminoma \[[@B4]\]. The mutation is of unknown significance, but according to Polyphen2 \[[@B11]\], this mutation is predicted to be probably damaging with a score of 0.996 (sensitivity: 0.55; specificity: 0.98), and in agreement with this, SiftBLink \[[@B12]\] indicates that substitution at position 1580 from Q to H is predicted to affect protein function with a score of 0.00 (less than 0.05 is usually regarded as evidence for a deleterious effect on protein function).

Recurrent "hotspot" somatic mutations exist in the RNase IIIb domain of DICER1 \[[@B10]\]. These hotspot mutations were mainly identified in SLCT, but of 26 TGCT analysed for the hotspots, a single non-seminomatous TGCT was found to possess c.5125G \> A, p.D1709N. It could not be determined if the mutation was germ-line or somatic in nature \[[@B10]\], but this mutation is functionally deleterious \[[@B13]\] and therefore could be etiologically related to the occurrence of the TGCT. Another study did not identify a *DICER1* mutation in a man with a seminoma, who was the relative of a patient with a PPB \[[@B5]\].

Recently, de Boer et al. reported finding only one presumed somatic RNase IIIb domain mutation (c.5174G \> A; p.R1725Q) among 96 TGCT for mutations in this domain \[[@B14]\]. Bioinformatic analysis of this variant gives varying results; whereas Polyphen2 \[[@B11]\] suggests that this mutation is predicted to be probably damaging with a score of 1.000 (sensitivity: 0.00; specificity: 1.00), SiftBLink \[[@B12]\] reports that substitution at position 1725 from R to Q is predicted to be tolerated with a score of 0.18.

In view of these previous studies, we wished to establish if germ-line *DICER1* mutations play a role in the etiology of TGCT, with the clinical aim of better counselling *DICER1* mutation carriers as to their cancer risks. We report here our analysis of germ-line DNA from 43 probands with a personal and family history of TGCT.

Methods
=======

Subjects
--------

Men with TGCT were recruited through an on-going case--control study at the Perelman School of Medicine at the University of Pennsylvania, which has been previously described \[[@B15],[@B16]\]. All patients completed a questionnaire, which includes self-reported information about family history of TGCT. For the current study, men with TGCT who reported a family history of at least one relative also with TGCT were selected (Table [1](#T1){ref-type="table"}). All studies were carried out in accordance with the Institutional Review Board (IRB) of the University of Pennsylvania with written consent (IRB study number: 703123).

###### 

Type of testicular germ cell tumor in 39 probands^\#^ plus degree of relatedness to familial case(s) of TGCT

                                                            **Degree of relatedness to affected relative**              
  -------------------------------------------------------- ------------------------------------------------ --- --- --- ----
  Seminoma, NOS                                                                   5                          3   4   0   12
  Embryonal carcinoma, NOS                                                        1                          3   1   1   6
  Teratoma, benign                                                                0                          0   1   0   1
  Teratocarcinoma                                                                 1                          0   2   2   5
  Choriocarcinoma combined with other germ cell elements                          0                          0   2   0   2
  Yolk sac tumor                                                                  0                          0   1   0   1
  Germ cell tumor, nonseminomatous                                                0                          0   1   0   1
  Mixed germ cell tumor (mixed teratoma and seminoma)                             1                          1   0   0   2
  Mixed germ cell tumor (mixed embryonal and seminoma)                            3                          1   2   0   6
  Mixed germ cell tumor (mixed yolk sac and seminoma)                             0                          0   0   1   1
  NSGCT (mixed yolk sac and teratoma, benign)                                     0                          0   1   0   1

\*First degree- parent, sib, child; second degree - aunt, uncle, grandparent, grandchild; third degree -- cousin; more than third -- second cousin. If more than one relative affected, only the closest degree of relatedness is included.

NSGCT -- Non-seminoma germ cell tumor; NOS -- not otherwise specified.

^**\#**^Family history could not be confirmed for two cases (seminoma and yolk sac tumor) and pathology could not be fully confirmed on a further two cases. These four cases were excluded from the table.

### Experimental details

We conducted High Resolution Melting Curve (HRM) analysis of *DICER1* \[GENBANK NM_177438.2**\]** exons 2--12, 14--19, 21, the 3' half of 23 and 24--27 using lymphocyte DNA from one proband from each family as described previously \[[@B3]\]. Briefly, we screened 22 of the 26 coding exons of *DICER1* by (HRM) using the LightScanner instrument (Idaho Technologies Inc., Utah, USA). The PCR reactions were done in 96 well plates from Bio Rad (Ontario, Canada) using the mastermix and the LCGreen Plus from Transition Technologies (Ontario, Canada). The plates were then transferred to the LightScanner instrument and the melted curves were analyzed by the software provided by Idaho Technologies. This technique was used as a presequencing selection for amplicons harboring variants. The PCR primers used are shown in Table [2](#T2){ref-type="table"}. All questionable melt curves were subjected to confirmatory Sanger sequencing, which due to the complexity of the HRM results, was used as the sole method of *DICER1* analysis for exons 13, 20, 22 and the 5' half of exon 23. Intron-exon boundaries were included in all analyses.

###### 

DICER1 oligonucleotide primers used in this study

   **Exon**  **Forward**                   **Reverse**                   **Size of fragment**   **Annealing temp. Sanger sequencing**   **Annealing temp. HRM**
  ---------- ----------------------------- ----------------------------- ---------------------- --------------------------------------- -------------------------
      2      GCAATGAAAGAAACACTGGATG        TCAAATCCAATTACCCAGCAG         358                    \[1\]                                   64
      3      TTTTGTAAATTTATTGGAGGACG       TCTGCCAGAAGAGATTAAATGAG       429                    \[1\]                                   64
      4      TTTTGGAGGATAACCTTGGAAC        AAATCAGACAACCAAGGCTACAG       390                    \[1\]                                   66
      5      TTGTCGTCAAGACATGCTTTC         TTTAATATTCATTCATTCATACACTGC   518                    \[1\]                                   66
      6      TAGTGGCATTTCCACCAAAC          GAATTCTTACTCTTGCCCATTCC       437                    \[1\]                                   69
      7      TTCTCACTACTGCAGTATTGATACCTT   GAGCCGCATTAAGCATATTTTC        303                    \[1\] (7 F modified)                    69
      8      AAATCCCAGTTAAACCCCAC          TCACATCACAACACAGGACG          554                    \[1\]                                   68
      9      TAAATCACCGTCGCCAAATC          AAATCACTCTACAGCTACCTCATGG     591                    \[1\]                                   69
      10     CATGTGTGTCAGAAATGACAGTTG      TTCCTATGGATACAAAGAATAACAAAG   431                    \[1\]                                   68
      11     AGCAGGTTACTTTGGAGTACTGAAG     AACTTTTATTGCTGCACGATACTG      498                    \[1\]                                   69
      12     TCACATTTCAAGTGCTCACC          TGAACATGTAGATGACTACAAAAGC     596                    \[1\]                                   69
      13     TTTTACTAGGCAGGACTTTTAAAGATG   AAGTGTTCATGGTGCATGATTC        585                    \[1\]                                   NA
      14     TTTGCAGTCCAGCTCATATTG         AAGCTGTGAATCGGAGAAAG          498                    \[1\]                                   69
      15     TAAGAAGTGTCATGCCTCGG          TCTAGTGGAGAAATAGAAGAGGCAC     468                    \[1\]                                   68
      16     GAAAGCATCATTTCTGTTCTGAAG      AAGAGAAAAACGACTCTTTAGC        443                    16R is new                              65
      17     TTCAGCATACTGTGTTCTACCTCTT     TTTTAGTAGAGACGAGGTTTCACC      484                    17 F is new                             69
      18     TGTAAAGGTGCCATTTAGCTTC        TTTGTGTGCAAAGCATCTCC          589                    \[1\]                                   69
      19     ATTGCACTTGAGGGATTCTTACC       TTTGTGATATATTAATGGGCCAAG      496                    \[1\]                                   67
      20     TTGGCCCATTAATATATCACA         TCTCACTCCAACTGTTATGGCTTA      594                    \[1\]                                   NA
     21-1    AATTGCTGTTGCTCTCAGCC          GAGTACATTCATCGCTGGGC          508                    \[1\]                                   68
     21-2    ACAAGCAGGAAATACCCGTG          ACTGCAAACCACTTTCAGGC          501                    \[1\]                                   68
      22     AAAGCATAGAATATGTGGGAATT       AGAAATTTGCCTCCATCAAA          584                    \[1\]                                   NA
     23-1    AACCCTTGCTTTTATTGAGTTTC       CAGGGCTTCCACACAGTCC           574                    \[1\]                                   NA
     23-2    AAACTGTGGTGTTGACACGG          TACAAGGCCAACACGATGAG          571                    \[1\]                                   68
      24     TGTGGGGATAGTGTAAATGCTTC       TGCCGTCAGAACTCTGAAAC          403                    \[1\]                                   68
    25-26    TGGACTGCCTGTAAAAGTGG          TGAACTTTTCCCCTTTGATG          450                    \[1\]                                   66
      27     CCTGTCTGTCGGGGGTATG           TCTGCCTTCAATTCATTCCA          448                    \[1\]                                   69

Key: HRM- High Resolution Melt. Oligonucleotide primers 16R and 17 F are new; they were designed specifically for High Resolution Melt analysis.

NA: Not Applicable -- the fragments amplified were not included in the HRM assay, they were sequenced instead.

\[1\] refers to the source of the oligonucleotide primer sequences. bp - base pairs.

Findings
--------

Among the 43 probands, we identified 14 different single nucleotide variants or polymorphisms, 12 of which have been previously reported, but no likely deleterious variants; notably no mutations that were predicted to truncate the protein were identified (Table [3](#T3){ref-type="table"}).

###### 

***DICER1*variants observed in 43 TGCT probands studied 14 samples had no SNPs**

  **Variant**                           **Predicted function**                         **Number of cases**
  ------------------------------------- ------------------------ --------------------- ------------------------
  c.1377-25 T \> A                      Likely non-pathogenic    Previously reported   1\*\*\*\*
  c.1509 + 32A \> G, rs144973109        Likely non-pathogenic    Previously reported   2
  c.1907 + 43C \> T, rs11624081         Likely non-pathogenic    Previously reported   6\*
  c.1907 + 105C \> T, rs2275182         Likely non-pathogenic    Previously reported   2\*
  c.1935G \> A p.P645P, rs61751177      Likely non-pathogenic    Previously reported   2^**§**^
  c.2041-91A \> G, rs2297730            Likely non-pathogenic    Previously reported   6, 1\*\*\*, 1^**§§§**^
  c.2116 + 59insA                       Likely non-pathogenic    Novel                 1\*\*\*
  c.2116 + 65A \> T, rs187825570        Likely non-pathogenic    Previously reported   1\*\*
  c.2804 + 62C \> T, rs117996122        Likely non-pathogenic    Previously reported   1^**§§**^
  c.2805-129G \> A                      Likely non-pathogenic    Novel                 1
  c.2997 T \> G p. L999L, rs12018992    Likely non-pathogenic    Previously reported   1\*\*\*
  c.3093 + 178 T \> C, rs17091820       Likely non-pathogenic    Previously reported   1\*\*\*
  c.5145C \> T p. L1715L, rs139500905   Likely non-pathogenic    Previously reported   1
  c.\*88 T \> A, rs13078                Likely non-pathogenic    Previously reported   15

\* one case has s11624081 in addition to this variant, and another has both rs61751177 and s11624081 (i.e. this person carries 3 variants).

\*\* has both rs2297730 and rs13078 in addition to this variant.

\*\*\* has rs2297730, rs17091820, rs12018992 and c.2116 + 59insA (i.e. this person carries 4 variants).

\*\*\*\* has rs144973109 and rs2297730 in addition to this variant.

^**§**^ one case has both rs2275182 and rs11624081 in addition to this variant (i.e. this person carries 3 variants), and one case has rs13078 in addition to this variant.

^**§§**^ has rs13078 in addition to this variant.

^**§§§**^ has rs13078 in addition to this variant.

TGCT account for 1 percent of all malignancies in males, but are the most common cancer among young men aged 15--35 years. Most germ cell tumors can be classified as seminomas or non-seminomas, while a small proportion are of mixed histology. Established risk factors include cryptorochidism, previous diagnosis of TGCT, subfertility and family history of TGCT (reviewed in \[[@B17],[@B18]\]).

Multiple epidemiological studies point toward a strong genetic basis for TGCT susceptibility. A large Swedish study estimates the genetic contribution of TGCT susceptibility to be about 25%, the third highest among cancers. Although familial aggregation of TGCT is rare with only 1.4% of families having two or more first degree relatives with the disease, multiple studies in different populations have shown that sons of an affected father are at 4--6 fold increased risk of developing TGCT while brothers of an affected male are at 8--10 fold increased risk, a familial relative risk that is much higher than most other cancers. Ethnic variability is also observed with an incidence five times higher in Caucasian males than in African-Americans (as reviewed by Rapley and Nathanson) \[[@B19]\].

A genome-wide linkage search for susceptibility loci initially identified a region on Xp27 as a possible candidate, however this finding was not replicated in an independent data set, the results of which suggested that no single highly penetrant allele is responsible for a substantial proportion of familial TGCT \[[@B20]\]. Candidate-gene analysis of a "gr/gr" deletion on the Y chromosome known to cause infertility, was found to be associated with a 2--3 fold risk of developing TGCT \[[@B21]\], however the deletion was present in only 2% of TGCT patients unselected for family history, explaining just 0.5% of the excess familial risk \[[@B22]\]. Other candidate-gene analyses have suggested associations with genes involved in immune and hormone regulation, however these findings have not been confirmed. Stronger evidence has come from recent genome-wide association studies that have identified six susceptibility loci implicating *KITLG, SPRY4, BAK1, TERT, ATF7IP and DMRT1* in disease pathogenesis. Nevertheless, these six loci together with the "gr/gr" deletion account for less than 15% of the excess familial risk, suggesting that many more risk alleles remain unaccounted for (reviewed in \[[@B19],[@B22]\]). A recent study suggested a possible role for *de novo* germline copy number variants (CNVs); such variants were seen in 7% of 43 TGCT trios, greater than the expected background rate of CNVs \[[@B23]\]. With these results in mind, whole exome/genome sequencing studies, focusing on large series of familial TGCTs is likely to be the next step in efforts to understand the genetic basis of TGCT.

The findings reported herein, when combined with the previously reported studies discussed above, suggest that neither germ-line nor somatic *DICER1* mutations are commonly associated with TGCT. These results strongly suggest that TGCTs do not fall within the spectrum of diseases associated with germ-line *DICER1* mutations and thus clinical screening for such cancers is not warranted in *DICER1* mutation carriers.
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